Details:

Alternative Title:
Emerg Infect Dis
Publisher's site:
http://dx.doi.org/10.3201/eid1705.101229
Personal Author:
Zoller, Thomas ; Junghanss, Thomas ; Kapaun, Annette ; Gjørup, Ida ; Richter, Joachim ; ... More +
Zoller, Thomas ; Junghanss, Thomas ; Kapaun, Annette ; Gjørup, Ida ; Richter, Joachim ; Hugo-Persson, Mats ; Mørch, Kristine ; Foroutan, Behruz ; Suttorp, Norbert ; Yürek, Salih ; Flick, Holger ; Less -
Description:
Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe malaria. We conducted a retrospective analysis for 25 travelers with severe malaria who returned from malaria-endemic regions and were treated at 7 centers in Europe. All patients survived. Treatment with IV artesunate rapidly reduced parasitemia levels. In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels. Five patients required a blood transfusion. Patients with posttreatment hemolysis had received higher doses of IV artesunate than patients without hemolysis. IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure.
Subject:
[+]
Adult
Antimalarials
Artemisinins
Female
Humans
Injections, Intravenous
Malaria, Falciparum
Male
Middle Aged
Retrospective Studies
Synopsis
Travel
Treatment Outcome

Source:
Emerg Infect Dis. 17(5):771-777. ;
Document Type:
Journal Article ;
Place as Subject:
Europe ;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:4a1d54b1773b5f6c7aebeb07f14e48d92dae981b7f33c805dd7d26809f444cd7
File Type:

Supporting Files

• 	10-1229-F.gif	gif
  	10-1229-F.jpg	jpeg
  	10-1229_finalS.nxml	txt
  	license.txt	txt

More +